Vimarsana
Biggest News Aggregation in the World

Page 21 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

Phathom Pharmaceuticals' erosive esophagitis treatment approved by FDA - Vimarsana News

Phathom Pharmaceuticals' erosive esophagitis treatment approved by FDA

The US Food and Drug Administration (FDA) has approved a potassium-competitive acid blocker (PCAB) as a new treatment for the healing of all grades of erosive esophagitis.

FDA Approves Novartis' Cosentyx To Treat Moderate To Severe Hidradenitis Suppurativa In Adults - Vimarsana News

FDA Approves Novartis' Cosentyx To Treat Moderate To Severe Hidradenitis Suppurativa In Adults

Novartis (NVS) said that the US Food and Drug Administration has approved Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of hidradenitis suppurativa.

FDA Approves First Ustekinumab Biosimilar With Interchangeability Designation - Vimarsana News

FDA Approves First Ustekinumab Biosimilar With Interchangeability Designation

Wezlana is the first biosimilar to reference Stelara approved in the United States. The product will launch in 2025.

Source: ajmc.com
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® - Vimarsana News

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA®

FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 yearsVOQUEZNA® met the primary endpoints and key secondary...

Adjuvant Pembrolizumab Improves OS in Select Patients With RCC After Nephrectomy - Vimarsana News

Adjuvant Pembrolizumab Improves OS in Select Patients With RCC After Nephrectomy

Adjuvant treatment with pembrolizumab significantly improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, meeting a key secondary end point of the phase 3 KEYNOTE-564 trial.